Transdermal delivery system
View Patent ↗An improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains an amine-functional drug in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of the amine-functional drug and is impermeable to the protonated form of the amine-functional drug.
1. A transdermal delivery system (TDS) comprising
a self-adhesive matrix containing a self-adhesive polymer and microreservoirs containing an amine-functional drug in free base form selected from the group consisting of fentanyl and oxybutynin,
wherein the microreservoirs are within the self-adhesive matrix and have a maximum diameter less than the thickness of the self-adhesive matrix; and
wherein the self-adhesive matrix is permeable to the amine-functional drug in free base form, and the self-adhesive matrix is substantially impermeable to the amine functional drug in protonated form.
2. The TDS of claim 1 , wherein the mean diameter of the microreservoirs is in the range of 0.5 to 20 μm.
3. The TDS of claim 1 , wherein the self-adhesive matrix is free of silica particles that can absorb salts of the amine functional drug at the TDS/skin interface.
4. The TDS of claim 1 , wherein the self-adhesive matrix comprises a silicone pressure sensitive adhesive.
5. The TDS of claim 1 , wherein the self-adhesive matrix comprises two or more silicone pressure sensitive adhesives.
6. The TDS of claim 5 , wherein the silicone pressure sensitive adhesive is a blend of a high tack silicone pressure sensitive adhesive comprising polysiloxane with a resin and a medium tack silicone pressure sensitive adhesive comprising polysiloxane with a resin.
7. The TDS of claim 1 , wherein the microreservoirs further contain at least one crystallization inhibitor comprising soluble polyvinylpyrrolidone, a copolymer of polyvinylpyrrolidone and vinyl acetate, polyethylene glycol, polypropylene glycol, glycerol, a fatty acid ester of glycerol and/or a copolymer of ethylene and vinyl acetate.
8. The TDS of claim 7 , wherein the at least one crystallization inhibitor comprises soluble polyvinylpyrrolidone.
9. The TDS of claim 1 , wherein the self-adhesive matrix contains 10 3 to 10 9 microreservoirs per cm 2 of the surface of the matrix.
10. The TDS of claim 1 , wherein the maximum diameter of the microreservoirs is not greater than 35 μm.
11. The TDS of claim 1 , further comprising a protective foil or sheet to be removed prior to use.
12. The TDS of claim 1 , further comprising a backing layer.
13. The TDS of claim 12 , wherein the backing layer is inert to the components of the matrix.
14. The TDS of claim 1 , wherein the self-adhesive matrix comprises a solid or semisolid semi-permeable polymer.
15. The TDS of claim 1 , wherein the self-adhesive matrix contains 10 6 to 10 9 microreservoirs per cm 2 of the surface of the matrix.
16. The TDS of claim 1 , further comprising a backing layer being inert to the component of the matrix, and a protective foil or sheet to be removed prior to use,
wherein the matrix contains 10 3 to 10 9 microreservoirs per cm 2 of the surface of the matrix, and wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix and is not greater than 35 μm.
17. A transdermal delivery system (TDS) comprising a self-adhesive matrix containing a self-adhesive polymer and microreservoirs containing an amine-functional drug in free base form selected from the group consisting of aminotetralin compounds,
wherein the microreservoirs are within the self-adhesive matrix and have a maximum diameter less than the thickness of the self-adhesive matrix; and
wherein the self-adhesive matrix is permeable to the amine-functional drug in free base form, and the self-adhesive matrix is substantially impermeable to the amine functional drug in protonated form.